{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:40:44Z","timestamp":1771918844134,"version":"3.50.1"},"reference-count":20,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Rituximab biosimilars are a cornerstone of treatment of advanced-stage follicular lymphoma (FL). This double-blind, parallel-group, phase 3 trial randomized (1:1) adults (\u226518 years) with stage III to IV indolent B-cell lymphoma, including grades 1 to 3a FL, to receive CT-P10 or rituximab (375 mg\/m2 IV), with cyclophosphamide, vincristine, and prednisone, every 3 weeks for 8 cycles (induction period). Patients achieving complete response (CR), unconfirmed CR, or partial response (PR) received CT-P10 or rituximab maintenance for 2 years (375 mg\/m2, every 8 weeks). Primary end points were previously reported, proving noninferiority of efficacy and pharmacokinetic equivalence of CT-P10 to rituximab. Secondary end points included overall response rate (PR+CR) during the induction period per 2007 International Working Group (IWG) criteria, survival analyses, and overall safety. Between 28 July 2014 and 29 December 2015, 140 patients were randomized (70 per group). Median follow-up was 39.9 months (interquartile range, 36.7-43.5). Per 1999 IWG criteria, 4-year Kaplan-Meier estimates (95% confidence interval [CI]) for CT-P10 and rituximab were 61% (47% to 73%) and 55% (36% to 70%) for progression-free survival (hazard ratio, 1.33 [95% CI, 0.67-2.63]; P=.409), respectively, and 88% (77% to 94%) and 93% (83% to 97%) for overall survival (5.29 [0.84-33.53]; P=.077). Overall, 90% (CT-P10) and 86% (rituximab) of patients experienced treatment-emergent adverse events. Long-term safety profiles were similar between groups. Findings confirm favorable outcomes for CT-P10\u2013treated patients with advanced-stage FL and demonstrate comparable long-term efficacy and overall safety between CT-P10 and rituximab. This trial was registered at www.clinicaltrials.gov as #NCT02162771.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004484","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T11:55:15Z","timestamp":1630670115000},"page":"3354-3361","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study"],"prefix":"10.1182","volume":"5","author":[{"given":"Christian","family":"Buske","sequence":"first","affiliation":[{"name":"Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie National Research Institute of Oncology, Krak\u00f3w, Poland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7168-6538","authenticated-orcid":false,"given":"Juan-Manuel","family":"Sancho","sequence":"additional","affiliation":[{"name":"Catalan Institute of Oncology-Josep Carreras Leukaemia Research Institute \u2013 Hospital Germans Trias i Pujol, Badalona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edvard","family":"Zhavrid","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy, Alexandrov National Cancer Centre of Belarus, Minsk, Belarus;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-8436","authenticated-orcid":false,"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-757X","authenticated-orcid":false,"given":"Jos\u00e9-\u00c1ngel","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9429-0138","authenticated-orcid":false,"given":"Aliaksandr","family":"Prokharau","sequence":"additional","affiliation":[{"name":"Department of Oncology, Minsk City Clinical Oncology Dispensary, Minsk, Belarus;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Vasilica","sequence":"additional","affiliation":[{"name":"Hematology Department, Fundeni Clinical Institute, Bucharest, Romania;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajnish","family":"Nagarkar","sequence":"additional","affiliation":[{"name":"Curie Manavata Cancer Centre, Nashik, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Kwak","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9897-2163","authenticated-orcid":false,"given":"SangJoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Celltrion, Inc., Incheon, South Korea; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SungHyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Celltrion, Inc., Incheon, South Korea; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KeumYoung","family":"Ahn","sequence":"additional","affiliation":[{"name":"Celltrion, Inc., Incheon, South Korea; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6853-4688","authenticated-orcid":false,"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Kasugai Municipal Hospital, Kasugai, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"issue":"2","key":"2021090315390216500_B1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajh.24937","article-title":"Follicular lymphoma: 2018 update on diagnosis and management","volume":"93","author":"Freedman","year":"2018","journal-title":"Am J Hematol."},{"issue":"10","key":"2021090315390216500_B2","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther."},{"key":"2021090315390216500_B3","author":"National Comprehensive Cancer Network"},{"key":"2021090315390216500_B4","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol."},{"key":"2021090315390216500_B5","author":"European Medicines Agency"},{"key":"2021090315390216500_B6","author":"US Food and Drug Administration"},{"issue":"3","key":"2021090315390216500_B7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/19420862.2018.1433976","article-title":"Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product","volume":"10","author":"Lee","year":"2018","journal-title":"MAbs."},{"issue":"5","key":"2021090315390216500_B8","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s12325-017-0522-y","article-title":"The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries [published correction appears in Adv Ther. 2017;34:1234]","volume":"34","author":"Gul\u00e1csi","year":"2017","journal-title":"Adv Ther."},{"issue":"8","key":"2021090315390216500_B9","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1016\/S2352-3026(17)30120-5","article-title":"Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial","volume":"4","author":"Kim","year":"2017","journal-title":"Lancet Haematol."},{"issue":"4","key":"2021090315390216500_B10","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021090315390216500_B11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021090315390216500_B12","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/bjh.16264","article-title":"First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4","volume":"188","author":"Walewski","year":"2020","journal-title":"Br J Haematol."},{"issue":"23","key":"2021090315390216500_B13","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J Clin Oncol."},{"issue":"1","key":"2021090315390216500_B14","first-page":"194","article-title":"Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance","volume":"35","author":"Kim","year":"2020","journal-title":"Korean J Intern Med (Korean Assoc Intern Med)."},{"issue":"10","key":"2021090315390216500_B15","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol."},{"issue":"2","key":"2021090315390216500_B16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12253-017-0234-2","article-title":"Efficacy and tolerability of a 2-year rituximab maintenance therapy in patients with advanced follicular lymphoma after induction of response with rituximab-containing first line-regimens (HUSOM Study)","volume":"24","author":"Schneider","year":"2018","journal-title":"Pathol Oncol Res."},{"issue":"14","key":"2021090315390216500_B17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2018-08-822148","article-title":"How I treat early-relapsing follicular lymphoma","volume":"133","author":"Casulo","year":"2019","journal-title":"Blood."},{"issue":"4","key":"2021090315390216500_B18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood."},{"issue":"8","key":"2021090315390216500_B19","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1016\/S2352-3026(17)30106-0","article-title":"Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study","volume":"4","author":"Jurczak","year":"2017","journal-title":"Lancet Haematol."},{"issue":"11","key":"2021090315390216500_B20","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S2352-3026(18)30157-1","article-title":"Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial","volume":"5","author":"Ogura","year":"2018","journal-title":"Lancet Haematol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/17\/3354\/1821174\/advancesadv2021004484.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/17\/3354\/1821174\/advancesadv2021004484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T11:56:03Z","timestamp":1630670163000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/17\/3354\/476707\/Long-term-efficacy-and-safety-of-CT-P10-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":20,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,9,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004484","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]}}}